Medicure Inc (MPH) - Net Assets
Based on the latest financial reports, Medicure Inc (MPH) has net assets worth CA$12.65 Million CAD (≈ $9.15 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$23.38 Million ≈ $16.91 Million USD) and total liabilities (CA$10.73 Million ≈ $7.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medicure Inc (MPH) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$12.65 Million |
| % of Total Assets | 54.1% |
| Annual Growth Rate | 4.96% |
| 5-Year Change | -29.88% |
| 10-Year Change | -66.86% |
| Growth Volatility | 219.41 |
Medicure Inc - Net Assets Trend (2000–2025)
This chart illustrates how Medicure Inc's net assets have evolved over time, based on quarterly financial data. See Medicure Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Medicure Inc (2000–2025)
The table below shows the annual net assets of Medicure Inc from 2000 to 2025. For live valuation and market cap data, see market cap of Medicure Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$12.91 Million ≈ $9.34 Million |
-37.87% |
| 2024-12-31 | CA$20.78 Million ≈ $15.03 Million |
+4.43% |
| 2023-12-31 | CA$19.90 Million ≈ $14.39 Million |
-5.28% |
| 2022-12-31 | CA$21.00 Million ≈ $15.19 Million |
+14.09% |
| 2021-12-31 | CA$18.41 Million ≈ $13.32 Million |
-3.84% |
| 2020-12-31 | CA$19.15 Million ≈ $13.85 Million |
-28.94% |
| 2019-12-31 | CA$26.94 Million ≈ $19.49 Million |
-67.77% |
| 2018-12-31 | CA$83.59 Million ≈ $60.47 Million |
+3.57% |
| 2017-12-31 | CA$80.71 Million ≈ $58.38 Million |
+107.17% |
| 2016-12-31 | CA$38.96 Million ≈ $28.18 Million |
+773.21% |
| 2015-12-31 | CA$4.46 Million ≈ $3.23 Million |
+214.08% |
| 2014-12-31 | CA$-3.91 Million ≈ $-2.83 Million |
+33.45% |
| 2013-12-31 | CA$-5.88 Million ≈ $-4.25 Million |
-35.83% |
| 2012-12-31 | CA$-4.33 Million ≈ $-3.13 Million |
-137.64% |
| 2011-12-31 | CA$-1.82 Million ≈ $-1.32 Million |
+93.23% |
| 2010-12-31 | CA$-26.89 Million ≈ $-19.45 Million |
-7.76% |
| 2009-12-31 | CA$-24.96 Million ≈ $-18.05 Million |
-27.68% |
| 2008-12-31 | CA$-19.55 Million ≈ $-14.14 Million |
-198.15% |
| 2007-12-31 | CA$-6.56 Million ≈ $-4.74 Million |
-119.11% |
| 2006-12-31 | CA$34.31 Million ≈ $24.82 Million |
-7.70% |
| 2005-12-31 | CA$37.17 Million ≈ $26.89 Million |
+406.39% |
| 2004-12-31 | CA$7.34 Million ≈ $5.31 Million |
-65.97% |
| 2003-12-31 | CA$21.57 Million ≈ $15.60 Million |
+336.42% |
| 2002-12-31 | CA$4.94 Million ≈ $3.58 Million |
-45.01% |
| 2001-12-31 | CA$8.99 Million ≈ $6.50 Million |
+133.31% |
| 2000-12-31 | CA$3.85 Million ≈ $2.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medicure Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6939127900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$86.90 Million | 673.15% |
| Total Equity | CA$12.91 Million | 100.00% |
Medicure Inc Competitors by Market Cap
The table below lists competitors of Medicure Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bitros Holding S.A
AT:MPITR
|
$8.08 Million |
|
AB Effectenbeteiligungen AG
STU:JPH
|
$8.08 Million |
|
Olive Resource Capital Inc
V:OC
|
$8.09 Million |
|
The Agency Group Australia Ltd
AU:AU1
|
$8.09 Million |
|
InTiCa Systems AG
F:IS7
|
$8.07 Million |
|
Reviva Pharmaceuticals Holdings Inc.
NASDAQ:RVPH
|
$8.07 Million |
|
NRB Industrial Bearings Limited
NSE:NIBL
|
$8.07 Million |
|
Gladiator Resources Ltd
AU:GLA
|
$8.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medicure Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 20,778,000 to 12,909,000, a change of -7,869,000 (-37.9%).
- Net loss of 7,097,000 reduced equity.
- Other factors decreased equity by 772,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-7.10 Million | -54.98% |
| Other Changes | CA$-772.00K | -5.98% |
| Total Change | CA$- | -37.87% |
Book Value vs Market Value Analysis
This analysis compares Medicure Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.87x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.30x to 0.87x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | CA$3.58 | CA$1.07 | x |
| 2001-12-31 | CA$4.87 | CA$1.07 | x |
| 2002-12-31 | CA$1.97 | CA$1.07 | x |
| 2003-12-31 | CA$5.80 | CA$1.07 | x |
| 2004-12-31 | CA$1.65 | CA$1.07 | x |
| 2005-12-31 | CA$7.42 | CA$1.07 | x |
| 2006-12-31 | CA$4.91 | CA$1.07 | x |
| 2007-12-31 | CA$-0.78 | CA$1.07 | x |
| 2008-12-31 | CA$-2.25 | CA$1.07 | x |
| 2009-12-31 | CA$-2.87 | CA$1.07 | x |
| 2010-12-31 | CA$-3.10 | CA$1.07 | x |
| 2011-12-31 | CA$-0.15 | CA$1.07 | x |
| 2012-12-31 | CA$-0.35 | CA$1.07 | x |
| 2013-12-31 | CA$-0.48 | CA$1.07 | x |
| 2014-12-31 | CA$-0.28 | CA$1.07 | x |
| 2015-12-31 | CA$0.28 | CA$1.07 | x |
| 2016-12-31 | CA$2.13 | CA$1.07 | x |
| 2017-12-31 | CA$4.45 | CA$1.07 | x |
| 2018-12-31 | CA$5.05 | CA$1.07 | x |
| 2019-12-31 | CA$1.80 | CA$1.07 | x |
| 2020-12-31 | CA$1.79 | CA$1.07 | x |
| 2021-12-31 | CA$1.80 | CA$1.07 | x |
| 2022-12-31 | CA$2.01 | CA$1.07 | x |
| 2023-12-31 | CA$1.91 | CA$1.07 | x |
| 2024-12-31 | CA$1.99 | CA$1.07 | x |
| 2025-12-31 | CA$1.24 | CA$1.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medicure Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.60%
- • Asset Turnover: 1.16x
- • Equity Multiplier: 1.93x
- Recent ROE (-54.98%) is below the historical average (-21.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -83.91% | -2378.79% | 0.03x | 1.15x | CA$-3.62 Million |
| 2001 | -43.12% | -2107.03% | 0.02x | 1.04x | CA$-4.77 Million |
| 2002 | -84.86% | -1738.09% | 0.05x | 1.07x | CA$-4.69 Million |
| 2003 | -27.77% | -1344.47% | 0.02x | 1.04x | CA$-8.15 Million |
| 2004 | -202.53% | -3237.37% | 0.05x | 1.37x | CA$-15.60 Million |
| 2005 | -33.92% | -4206.05% | 0.01x | 1.04x | CA$-16.32 Million |
| 2006 | -92.41% | -533.30% | 0.10x | 1.74x | CA$-35.13 Million |
| 2007 | 0.00% | -2554.48% | 0.06x | 0.00x | CA$-56.75 Million |
| 2008 | 0.00% | -277.85% | 0.50x | 0.00x | CA$-11.36 Million |
| 2009 | 0.00% | -166.79% | 0.56x | 0.00x | CA$-3.04 Million |
| 2010 | 0.00% | -55.51% | 0.70x | 0.00x | CA$675.26K |
| 2011 | 0.00% | 487.53% | 1.01x | 0.00x | CA$23.57 Million |
| 2012 | 0.00% | -98.91% | 0.76x | 0.00x | CA$-2.14 Million |
| 2013 | 0.00% | -32.45% | 1.40x | 0.00x | CA$-1.05 Million |
| 2014 | 0.00% | 22.71% | 1.38x | 0.00x | CA$2.44 Million |
| 2015 | 37.40% | 7.56% | 1.04x | 4.76x | CA$1.22 Million |
| 2016 | 75.02% | 73.21% | 0.18x | 5.82x | CA$23.97 Million |
| 2017 | 53.80% | 160.03% | 0.21x | 1.60x | CA$35.35 Million |
| 2018 | 4.70% | 13.49% | 0.28x | 1.24x | CA$-4.43 Million |
| 2019 | -73.44% | -98.08% | 0.48x | 1.57x | CA$-22.48 Million |
| 2020 | -35.75% | -58.96% | 0.34x | 1.78x | CA$-8.76 Million |
| 2021 | -3.95% | -3.34% | 0.77x | 1.54x | CA$-2.57 Million |
| 2022 | 6.50% | 5.92% | 0.77x | 1.42x | CA$-735.50K |
| 2023 | -4.63% | -4.25% | 0.77x | 1.41x | CA$-2.91 Million |
| 2024 | -5.00% | -4.74% | 0.74x | 1.43x | CA$-3.12 Million |
| 2025 | -54.98% | -24.60% | 1.16x | 1.93x | CA$-8.39 Million |
Industry Comparison
This section compares Medicure Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $713,486,636
- Average return on equity (ROE) among peers: -56.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medicure Inc (MPH) | CA$12.65 Million | -83.91% | 0.85x | $8.08 Million |
| Aurora Cannabis Inc (ACB) | $1.69 Million | -10.52% | 0.00x | $171.89 Million |
| Amotiv Limited (AOV) | $795.11 Million | 0.54% | 0.21x | $576.83 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-6.45 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $3.46 Million | -426.03% | 4.09x | $12.28 Million |
| Avant Brands Inc (AVNT) | $32.85 Million | -68.65% | 0.81x | $6.98 Million |
| Bausch Health Companies Inc (BHC) | $5.94 Billion | 40.44% | 5.31x | $1.87 Billion |
| CanadaBis Capital Inc (CANB) | $2.63 Million | 23.10% | 4.88x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $266.93 Million | -39.33% | 0.51x | $12.41 Million |
| Cipher Pharmaceuticals Inc (CPH) | $18.41 Million | -56.20% | 0.05x | $297.74 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $76.24 Million | -32.43% | 0.15x | $118.76 Million |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more